Feb 13 (Reuters) - Johnson & Johnson JNJ.N on Thursday said it will discontinue a late-stage study of an experimental E.coli vaccine that it was developing in partnership with Sanofi SASY.PA.
The drugmaker said its decision was based on the recommendation of an independent committee that found the vaccine candidate may not be sufficiently effective.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Savio D'Souza)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.